Skip to main content
How strong is your knowledge on continuous glucose monitors? Take the quiz to test your expertise!
>
Osteoporosis
Disease State Hub
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Agitation in Alzheimer Disease
COVID-19
Danon Disease
Depression Care 360
Diabetes
Diabetes Technology
Digital Health Solutions in Diabetes
Dry Eye Disease
Endometrial Cancer
HIV Management
IgG4-Related Disease
Lupus Nephritis
MASH
Pain Management
Type 2 Diabetes
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Multidisciplinary Roundtables
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
COVID-19
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Uterine Polyps
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Get Permissions
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Agitation in Alzheimer Disease
COVID-19
Danon Disease
Depression Care 360
Diabetes
Diabetes Technology
Digital Health Solutions in Diabetes
Dry Eye Disease
Endometrial Cancer
HIV Management
IgG4-Related Disease
Lupus Nephritis
MASH
Pain Management
Type 2 Diabetes
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Multidisciplinary Roundtables
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
COVID-19
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Uterine Polyps
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Get Permissions
Pharmacology
Quiz: Pharmacological Management of Osteoporosis
Copied to clipboard
<section><h2><h2><strong>Quiz: Guideline for the Pharmacological Management of Osteoporosis in Postmenopausal Women</strong></h2></h2></section><section><h2><h2><strong></strong>The guideline recommends initial treatment with bisphosphonates in postmenopausal women at high risk of fractures. Which bisphosphonate is NOT recommended to reduce nonvertebral or hip fracture risk?</h2></h2></section><section><h3><h2><strong></strong>True or False: A bisphosphonate holiday is operationally defined as a temporary discontinuation of bisphosphonate for up to 3 years.</h2></h3></section><section><h3><h2>The guideline recommends using denosumab as an alternative initial treatment among postmenopausal women with osteoporosis who are at high risk for osteoporotic fractures. What is the recommended dosage of denosumab?</h2></h3></section><section><h3><h2><strong></strong>According to a formal amendment of the guideline, what agent that was recently approved by the FDA can now be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture?</h2></h3></section><section><h2><h2><strong>Better luck next time!</strong></h2></h2></section><section><h3><h2><strong>Nice job!</strong></h2></h3></section>
